Search Results
10
Everything
Search Filters
Tag
Cns
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
March 20, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
March 11, 2025 08:33 ET
|
Kaerus Bioscience
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
March 11, 2025 06:00 ET
|
Kaerus Bioscience
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
February 18, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 19, 2024 08:00 ET
|
Alumis Inc.
In a Phase 1 trial, oral TYK2 inhibitor A-005 was well tolerated and demonstrated ability to cross blood-brain barrier; Phase 2 to start in MS in 2H 2025.
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
October 28, 2024 08:00 ET
|
ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines
October 28, 2024 03:00 ET
|
ViaNautis Bio
ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use...
ViaNautis Appoints Ray Jupp as Chief Scientific Officer
October 21, 2024 02:00 ET
|
ViaNautis Bio
ViaNautis Appoints Ray Jupp as Chief Scientific Officer Cambridge, UK 21 October – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic...
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer
October 18, 2024 07:00 ET
|
ViaNautis Bio
ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer Cambridge UK, 18 October 2024 – ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront...